Clinical trials: Urinary Bladder, Neurogenic
Spinal Cord Injury, Neurogenic Bladder
Multifaceted Treatment of Catheter-related Urinary Tract Infection
The specific objective of this clinical trial is to demonstrate that a multifaceted approach for treatment for catheter-related urinary tract infection (UTI) in patients with spinal cord injury is effective and feasible.
- Conditions
- Spinal Cord Injury, Neurogenic Bladder, Urinary Tract Infection
- Trial name
- NCT00732238
- Testing
- Shortened course of antibiotic therapy, Standard Therapy
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- US Department of Veterans Affairs
Lower Urinary Tract Symptoms
A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters
A urodynamic study (UDS) is a common procedure done to learn more about the cause of urinary symptoms. For some patients, UDS can be associated with anxiety or discomfort.
- Trial name
- NCT05883332
- Testing
- Self-Administered Nitrous Oxide, Oxygen
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Neurogenic Detrusor Overactivity
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity.
- Trial name
- NCT00712322
- Testing
- Darifenacin
- Where
- 12 sites in United States, Colombia
- Volunteers
- 35 people
- Sponsor
- Warner Chilcott
Hydronephrosis, Neurogenic Bladder
Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology
Primary objective was to determine efficacy of Alfuzosin in the treatment of children and adolescents 2-16 years of age with newly diagnosed or progressive hydronephrosis due to elevated detrusor Leak Point Pressure [LPP] of…
- Trial name
- Alfahydro (NCT00576823)
- Testing
- Alfuzosin
- Where
- 12 sites in Bulgaria, Canada and 10 more
- Volunteers
- 25 people
- Sponsor
- Sanofi
Neurogenic Bladder Dysfunction
Chronic Electrical Stimulation to Reduce Bladder Hyperreflexia
Bladder spasms after spinal cord injury (SCI) can result in incontinence, urinary tract infections, kidney damage, trigger dangerous increases in blood pressure and decrease independence and quality of life.
- Trial name
- NCT03472599
- Testing
- Genital Nerve Stimulation
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- VA Office of Research and Development
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Chronic Spinal Cord Injury, Neurogenic Bowel
Home Neuromodulation of the Neurogenic Bladder in Chronic Spinal Cord Injury With Transcutaneous Tibial Nerve Stimulation
Determine the safety, feasibility, compliance, and efficacy of a daily home TTNS protocol in chronic SCI provided by self or caregiver for 4 weeks.
- Trial name
- HomeTTNS (NCT03458871)
- Testing
- 4-week TTNS home-based protocol
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The University of Texas Health Science Center, Houston
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for…
- Trial name
- CONTENT2 (NCT02660359)
- Testing
- Botulinum toxin type A
- Where
- 82 sites in Argentina, Australia and 14 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Urinary Bladder, Neurogenic
Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder
Neurogenic bladder patients may have symptoms of urinary frequency, urgency, urgency incontinence and voiding symptoms due to bladder dysfunction arising from their underlying neurologic condition.
- Trial name
- NCT02582151
- Testing
- EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine
- Volunteers
- 30 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Detrusor Function, Overactive
Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity
The purpose of this study is to evaluate the effects and tolerability (how well a participant can stand a particular medicine or treatment) of flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel) including safety and…
- Trial name
- RONDO (NCT01796548)
- Testing
- Oxybutinin Extended-Release
- Where
- 3 sites in Thailand
- Volunteers
- 17 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Bladder, Neurogenic
Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder
Aim of this study is to evaluate the efficacy and safety of a range of doses of tamsulosin hydrochloride as treatment in children with an elevated detrusor leak point pressure associated with a known neurological deficit
- Trial name
- NCT00796614
- Testing
- tamsulosin hydrochloride
- Where
- 52 sites in United States, Belgium and 11 more
- Volunteers
- 231 people
- Sponsor
- Boehringer Ingelheim
Neurogenic Bladder
Augmentation Cystoplasty Using an Autologous Neo-Bladder
Subjects with neurogenic bladder secondary to spina bifida refractory to medical treatment will be enrolled. The hypothesis is that augmentation cystoplasty using an autologous neo-bladder construct will significantly increase…
- Trial name
- NCT00419120
- Testing
- Autologous neo bladder construct
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tengion
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.
- Trial name
- NCT00311376
- Testing
- botulinum toxin Type A (200U), botulinum toxin Type A (300U)
- Where
- 14 sites in United States, Australia and 12 more
- Volunteers
- 416 people
- Sponsor
- Allergan
Overactive Detrusor, Neurogenic Bladder
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition.
- Trial name
- NCT01192568
- Testing
- Oxybutynin
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- AbbVie
Urinary Tract Infections, Bladder, Neurogenic
A Biochip for Rapid Diagnosis of Complicated Urinary Tract Infection
The purpose of this proposal is clinical validation of an electrochemical biochip for rapid pathogen identification and antibiotic susceptibility determination.
- Trial name
- NCT00591240
- Where
- United States
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Spinal Cord Injury, Acute, Neurogenic Bladder
Sacral Nerve Stimulation in Improving Bladder Function After Acute Traumatic Spinal Cord Injury
The purpose of this study is to see what effects sacral neuromodulation has on bladder function and quality of life in patients with acute spinal cord injury.
- Conditions
- Spinal Cord Injury, Acute, Neurogenic Bladder, Incontinence, Urinary Tract Infections
- Trial name
- NCT03083366
- Testing
- PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Detrusor Hyperreflexia
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
- Trial name
- NCT00224029
- Testing
- Oxybutynin transdermal system
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Watson Pharmaceuticals
Spinal Cord Injury
High Frequency SARS for Neurogenic Bladder and Bowel Emptying
The purpose of this study is to determine if bladder emptying can be achieved using stimulation of the sacral roots at certain frequencies. Neurogenic bladder dysfunction occurs after spinal cord injury (SCI).
- Trial name
- SARS600 (NCT05214378)
- Testing
- Finetech-Brindley Sacral Anterior Roots Stimulation System
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- VA Office of Research and Development
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to explore the effectiveness and safety of several doses of botulinum toxin type A in treating overactive bladder in patients with spinal cord injury.
- Trial name
- NCT00575016
- Testing
- botulinum toxin Type A (50U); botulinum toxin Type A (200U), botulinum toxin Type A (100U); botulinum toxin Type A (200U), botulinum toxin Type A (200U)
- Where
- 6 sites in Egypt, Greece and 4 more
- Volunteers
- 74 people
- Sponsor
- Allergan